A leaner Elon Musk recently revealed that he takes Mounjaro for weight loss.
Musk shared this information in a festive social media post, where he dressed as Santa Claus with a flowing white beard.
He humorously referred to himself as “Ozempic Santa”, joking it was “like Cocaine Bear, but Santa and Ozempic.”
Musk clarified that he uses Mounjaro instead of Ozempic but noted the former lacks a catchy nickname.
He mentioned preferring Mounjaro due to fewer side effects compared to high doses of Ozempic.
Musk described Ozempic’s side effects as making him "fart and burp like Barney from the Simpsons."
Both Mounjaro and Ozempic belong to the GLP-1 inhibitor class, originally developed to regulate blood sugar and insulin for diabetes patients.
Americans are increasingly using GLP-1 inhibitors for successful weight loss.
Musk, who is 53, stated that Mounjaro seems more effective with less discomfort.
He has long supported widespread use of GLP-1 inhibitors to combat obesity in the U.S.
Musk’s support for GLP-1 inhibitors has drawn praise from prominent voices, including a liberal talk show host.
Musk, who dislikes exercise, has previously admitted to using Wegovy, another GLP-1 inhibitor, in 2022.
His endorsement has stirred debate about the role of medications versus lifestyle changes in tackling obesity.
Key Take-Home Points
- Musk revealed he uses Mounjaro for weight loss, favoring it over Ozempic due to fewer side effects.
- GLP-1 inhibitors, like Mounjaro and Ozempic, are being repurposed from diabetes treatment to aid weight loss.
- Musk's position supports medication use for obesity, while critics push for diet-based solutions.
- His statements have reignited discussions about obesity management, medications, and personal choices.
- Mounjaro continues to gain popularity as a promising option with fewer side effects.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.